|Mr. Yatomi-Clarke Steven Lee||MD, CEO & Director||404.96k||N/A||N/A|
|Prof. Said M. Sebti||Chief Scientific Officer||161.79k||N/A||N/A|
|Dr. Terrence G. Chew||Chief Medical Officer||158.77k||N/A||1947|
|Ms. Melanie Jaye Leydin C.A., B.Bus, CA||Company Sec.||102k||N/A||1973|
|Dr. Claudia Gregorio-King||VP of Operations||N/A||N/A||N/A|
Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of a range of cancers in Australia. The company's lead drug candidate is PTX-200, which is in Phase II clinical trial for negative breast cancer, as well as Phase IB clinical trial in relapsed and refractory ovarian cancer and acute leukemia; and PTX-100, a treatment that has completed Phase I clinical trial for solid tumors. It has a collaboration agreement with Carina Biotech to develop next generation cellular therapies. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited is based in South Melbourne, Australia.
Prescient Therapeutics Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.